KR920001377B1 - 인체 면역 인터페론 단백질의 제조방법 - Google Patents

인체 면역 인터페론 단백질의 제조방법 Download PDF

Info

Publication number
KR920001377B1
KR920001377B1 KR1019830004437A KR830004437A KR920001377B1 KR 920001377 B1 KR920001377 B1 KR 920001377B1 KR 1019830004437 A KR1019830004437 A KR 1019830004437A KR 830004437 A KR830004437 A KR 830004437A KR 920001377 B1 KR920001377 B1 KR 920001377B1
Authority
KR
South Korea
Prior art keywords
arg
added
solution
hours
pme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR1019830004437A
Other languages
English (en)
Korean (ko)
Other versions
KR840006676A (ko
Inventor
마사까즈 기꾸찌
고오조 쓰까모도
쓰또무 구로가와
Original Assignee
다께다야꾸힝고오교 가부시끼가이샤
구라바야시 이꾸시로
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다께다야꾸힝고오교 가부시끼가이샤, 구라바야시 이꾸시로 filed Critical 다께다야꾸힝고오교 가부시끼가이샤
Publication of KR840006676A publication Critical patent/KR840006676A/ko
Application granted granted Critical
Publication of KR920001377B1 publication Critical patent/KR920001377B1/ko
Expired legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1019830004437A 1982-11-22 1983-09-22 인체 면역 인터페론 단백질의 제조방법 Expired KR920001377B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/JP1982/000445 WO1984002129A1 (fr) 1982-11-22 1982-11-22 Proteine de l'interferon immun humain et son procede de preparation
JPPCT/JP82/00445 1982-11-22
JPJP82/0045 1982-11-22

Publications (2)

Publication Number Publication Date
KR840006676A KR840006676A (ko) 1984-12-01
KR920001377B1 true KR920001377B1 (ko) 1992-02-11

Family

ID=13762365

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830004437A Expired KR920001377B1 (ko) 1982-11-22 1983-09-22 인체 면역 인터페론 단백질의 제조방법

Country Status (18)

Country Link
EP (1) EP0110044A1 (enExample)
JP (4) JPS59186995A (enExample)
KR (1) KR920001377B1 (enExample)
AU (1) AU570219B2 (enExample)
DK (1) DK164063C (enExample)
ES (1) ES527414A0 (enExample)
FI (1) FI81832C (enExample)
GR (1) GR79035B (enExample)
HU (1) HU209152B (enExample)
IE (1) IE57053B1 (enExample)
IL (1) IL69791A (enExample)
MC (1) MC1553A1 (enExample)
NO (1) NO169725C (enExample)
NZ (1) NZ205667A (enExample)
PH (1) PH20024A (enExample)
PT (1) PT77573B (enExample)
WO (1) WO1984002129A1 (enExample)
ZA (1) ZA837057B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582824A (en) * 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
WO1984002129A1 (fr) * 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Proteine de l'interferon immun humain et son procede de preparation
EP0133767B1 (en) * 1983-08-04 1991-04-03 The Green Cross Corporation Gamma interferon composition
JPS6034919A (ja) * 1983-08-04 1985-02-22 Green Cross Corp:The ガンマ・インタ−フェロン組成物
ZA846554B (en) * 1983-09-20 1985-04-24 Hoffmann La Roche Immune interferon and method for its purification
FR2556365B1 (fr) * 1983-12-09 1987-07-31 Transgene Sa Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g
MX9203641A (es) * 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4499014A (en) * 1984-02-07 1985-02-12 Interferon Sciences, Inc. Method for purifying gamma-interferon
DE3426077A1 (de) * 1984-07-14 1986-01-23 Dr. Karl Thomae Gmbh, 7950 Biberach Monoklonale antikoerper gegen humanes ifn-(gamma), diese antikoerper produzierende hybridzellinien, verwendung der neuen antikoerper und verfahren zu deren herstellung
DE3432196A1 (de) * 1984-09-01 1986-03-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neues mechanisches aufschlussverfahren von bakterienzellen zur isolierung von rekombinant hergestellten peptiden
JPH0653067B2 (ja) * 1984-09-11 1994-07-20 武田薬品工業株式会社 新規ハイブリドーマおよびその製造法
GB2164650A (en) * 1984-09-25 1986-03-26 Fujisawa Pharmaceutical Co Process for production of y-interferon
US4946674A (en) * 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
US4873312A (en) * 1985-04-25 1989-10-10 Amgen Method for purifying interferon and composition of matter produced thereby
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
GB8719108D0 (en) * 1987-08-12 1987-09-16 Natural Environment Res Expression vectors
DE3829180A1 (de) * 1988-08-29 1990-03-08 Boehringer Ingelheim Int Neues arzneimittel zur vorbeugung und behandlung von durch primaere immundefekte verursachte krankheiten
US7230081B1 (en) 1999-11-12 2007-06-12 Maxygen Holdings, Ltd. Interferon gamma conjugates
KR20020065517A (ko) 1999-11-12 2002-08-13 맥시겐 홀딩스 리미티드 인터페론 감마 접합체
US7038015B2 (en) 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
AU2003239774A1 (en) 2002-07-03 2004-01-23 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
EP2364995A1 (en) 2004-12-23 2011-09-14 Molmed SpA Conjugation product
US20090148435A1 (en) 2007-10-30 2009-06-11 Genentech, Inc. Antibody purification by cation exchange chromatography

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65475A0 (en) * 1981-04-17 1982-07-30 Meloy Lab Production of immune interferon and its mrna
US4376821A (en) * 1981-04-17 1983-03-15 Meloy Laboratories, Inc. Production of human IFN-gamma (immune) interferon
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
JPS58110548U (ja) * 1982-01-22 1983-07-28 株式会社東海理化電機製作所 自動車用ミラ−の駆動装置
EP0088540A3 (en) * 1982-02-22 1984-10-17 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing human immune interferon-like polypeptides
IL68100A0 (en) * 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof
JPH0787797B2 (ja) * 1982-05-20 1995-09-27 サントリー株式会社 ヒト・ガンマ・インタ−フエロン様ポリペプチドの製造法
US4681848A (en) * 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
WO1984002129A1 (fr) * 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Proteine de l'interferon immun humain et son procede de preparation
JP2526750B2 (ja) * 1991-07-30 1996-08-21 株式会社ユアサコーポレーション リチウム二次電池

Also Published As

Publication number Publication date
AU570219B2 (en) 1988-03-10
DK430683A (da) 1984-05-23
JPH0536414B2 (enExample) 1993-05-31
ES8504938A1 (es) 1985-04-16
PT77573A (en) 1983-11-01
FI81832C (fi) 1990-12-10
JPS6411639B2 (enExample) 1989-02-27
DK430683D0 (da) 1983-09-21
NZ205667A (en) 1987-01-23
NO169725C (no) 1992-07-29
ZA837057B (en) 1984-04-25
WO1984002129A1 (fr) 1984-06-07
HU209152B (en) 1994-03-28
KR840006676A (ko) 1984-12-01
NO169725B (no) 1992-04-21
JPS59186995A (ja) 1984-10-23
MC1553A1 (fr) 1984-08-31
IL69791A (en) 1994-05-30
JPS59220190A (ja) 1984-12-11
DK164063C (da) 1992-09-28
IE832216L (en) 1984-05-22
JPS63211240A (ja) 1988-09-02
FI81832B (fi) 1990-08-31
IE57053B1 (en) 1992-04-08
JPH06316532A (ja) 1994-11-15
PH20024A (en) 1986-09-01
EP0110044A1 (en) 1984-06-13
GR79035B (enExample) 1984-10-02
FI833525L (fi) 1984-05-23
NO833659L (no) 1984-05-23
DK164063B (da) 1992-05-04
ES527414A0 (es) 1985-04-16
FI833525A0 (fi) 1983-09-29
AU1934683A (en) 1984-06-28
PT77573B (en) 1986-03-18

Similar Documents

Publication Publication Date Title
KR920001377B1 (ko) 인체 면역 인터페론 단백질의 제조방법
JP2515308B2 (ja) ヒト免疫インタ−フエロン
KR860001558B1 (ko) 인터페론의 제조방법
KR910001726B1 (ko) 펩티드의 제조방법
EP0155549B1 (en) Dna encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
FI80719C (fi) Foerfarande foer framstaellning av maenniskointerferonpolypeptider.
EP0118617B1 (en) Interleukin-2 polypeptides
CA1214411A (en) Process for the preparation of immune interferon
US5714581A (en) Polypeptide derivatives of human granulocyte colony stimulating factor
PL149079B1 (en) Method of obtaining polypeptides of ifn-beta type
JP2862870B2 (ja) 新規ペプチド
EP0211321A2 (en) Amino-acid composition, method for its production and medical composition containing it
KR870000511B1 (ko) 발현 비히클의 제조방법
JPS6034994A (ja) 新規ポリペプチドおよびその用途
WO1984004745A1 (fr) Nouveaux polypeptides et leur utilisation
JPH0242986A (ja) 新規なヒト生理活性ポリペプチドをコードするｄｎａ
CS273182B2 (en) Method of expressive vector production capable to give mature human leucocytic interferon in transformed strain of escherichia coli by means of expression

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 19971230

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19990212

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19990212

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000